Epstein-Barr virus (EBV), also known as human herpesvirus 4, is transmitted via saliva and has a propensity to infect B-cells. The virus can persist in humans asymptomatically throughout their lifetime, however can also result in delayed complications such as lymphoproliferative disorders. One of the most noteworthy risk factors for the development of EBV positive mucocutaneous ulcer is immunosuppression. This condition has been reported in the setting of iatrogenic immunosuppression (56%), advanced age-associated immunosenescence (40%), and primary immunosuppression (4%).